As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...

Low proteinuria does not indicate better kidney outcomes or treatment response in patients with lupus nephritis; ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the formation of a new philanthropic venture fund Lupus Ventures. The Fund is dedicated to advancing ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs ...

It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Systemic Lupus Erythematosus is one of the most complex autoimmune diseases seen in modern medicine, affecting multiple organs and presenting differently from one patient to another. Often referred to ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...